Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclibJamie O. Brett, Seth A. Wander, Siobhan Dunne et al.|Cancer Research|2022Cited by 1